Ultragenyx Securities Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RARE?
Source: Globenewswire
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit, as failing to do so may result in the loss of compensation opportunities.
- Stock Price Plunge: Following the December 26, 2025 announcement that Ultragenyx's setrusumab (UX143) failed to show a statistically significant reduction in fracture rates in its Phase III studies, the stock price plummeted by approximately 42%, from $34.19 to $19.72, indicating severe market pessimism regarding the company's future prospects.
- Legal Allegations: The lawsuit alleges that Ultragenyx and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, thereby affecting investor confidence and future operations.
- Cost Reduction Plans: Ultragenyx stated it would evaluate its operational plans and promptly implement significant expense reductions in response to the stock price drop, a strategy that may impact its ongoing R&D and marketing efforts while attempting to stabilize its financial situation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.180
Low
35.00
Averages
61.65
High
120.00
Current: 20.180
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit, as failing to do so may result in the loss of compensation opportunities.
- Stock Price Plunge: Following the December 26, 2025 announcement that Ultragenyx's setrusumab (UX143) failed to show a statistically significant reduction in fracture rates in its Phase III studies, the stock price plummeted by approximately 42%, from $34.19 to $19.72, indicating severe market pessimism regarding the company's future prospects.
- Legal Allegations: The lawsuit alleges that Ultragenyx and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, thereby affecting investor confidence and future operations.
- Cost Reduction Plans: Ultragenyx stated it would evaluate its operational plans and promptly implement significant expense reductions in response to the stock price drop, a strategy that may impact its ongoing R&D and marketing efforts while attempting to stabilize its financial situation.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical, involving investors who purchased stock between August 3, 2023, and December 26, 2025, highlighting serious concerns over the company's transparency.
- False Statements Allegations: The lawsuit alleges that Ultragenyx made misleading statements regarding the efficacy of its drug setrusumab in the Phase III Orbit study, failing to disclose the risk that patients might not achieve a statistically significant reduction in annualized fracture rate, potentially leading to misjudgments about the company's prospects.
- Investor Action: Affected investors must apply for lead plaintiff status by April 6, 2026, to represent all impacted investors in the litigation, indicating a proactive stance and engagement from the investor community in legal proceedings.
- Law Firm's Role: Kessler Topaz Meltzer & Check, LLP is a leading law firm focused on securities fraud class actions, representing both individual and institutional investors, underscoring its significance in safeguarding investor rights.
See More
Ultragenyx Pharmaceutical Class Action Notice Issued
- Shareholder Lawsuit Notice: The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), encouraging those who purchased shares during the class period from August 3, 2023, to December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- False Statements Allegations: The complaint alleges that Ultragenyx provided overwhelmingly positive statements while concealing significant adverse facts about setrusumab's potential, misleading investors and impacting their decision-making regarding the company's future.
- Clinical Trial Failure: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints, resulting in a dramatic stock price drop of approximately 42.32% in one day, from $34.19 to $19.72, severely undermining investor confidence.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected during the legal proceedings.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock between August 3, 2023, and December 26, 2025, highlighting investor concerns over potential risks associated with the company.
- Study Results Fail: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing clinical fracture rates, leading to a dramatic stock price drop of approximately 42.32% in a single day, from $34.19 to $19.72 per share, reflecting market disappointment in the company's prospects.
- Misleading Statements: The lawsuit alleges that the company provided overly optimistic statements to investors regarding setrusumab's ability to significantly reduce fracture rates, while the study designs and outcomes were not as effective as claimed by management, causing investors to purchase shares at artificially inflated prices.
- Investor Action Advice: Affected shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs, emphasizing the importance of corporate governance and accountability of management in light of the allegations.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta patients, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff to share in any potential recovery, indicating the urgency and importance of investor participation in the legal process.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx and Mereo Face Class Action Lawsuits
- Lawsuit Background: Bragar Eagel & Squire, P.C. has alerted investors that Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc are facing class action lawsuits, with a deadline of April 6, 2026, for investors to apply as lead plaintiffs, indicating significant investor concern over potential risks associated with these companies.
- Ultragenyx Lawsuit Details: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing fracture rates, causing its stock price to plummet from $34.19 to $19.72, a decline of 42.32%, reflecting market disappointment in the study results.
- Mereo Lawsuit Details: Mereo BioPharma faces similar allegations as its Phase 3 ORBIT and COSMIC studies did not meet the primary endpoint of reducing annualized fracture rates, leading to a drastic drop in its stock price from $2.31 to $0.29, a decline of over 87.7%, showcasing extreme investor pessimism regarding its prospects.
- Investor Impact: Both companies are accused of failing to disclose research risks adequately, resulting in shareholders purchasing stocks at inflated prices; the initiation of class action lawsuits may severely impact their future financing and market confidence, exacerbating investor anxiety.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit, as failing to do so may result in the loss of compensation opportunities.
- Stock Price Plunge: Following the December 26, 2025 announcement that Ultragenyx's setrusumab (UX143) failed to show a statistically significant reduction in fracture rates in its Phase III studies, the stock price plummeted by approximately 42%, from $34.19 to $19.72, indicating severe market pessimism regarding the company's future prospects.
- Legal Allegations: The lawsuit alleges that Ultragenyx and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, thereby affecting investor confidence and future operations.
- Cost Reduction Plans: Ultragenyx stated it would evaluate its operational plans and promptly implement significant expense reductions in response to the stock price drop, a strategy that may impact its ongoing R&D and marketing efforts while attempting to stabilize its financial situation.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical, involving investors who purchased stock between August 3, 2023, and December 26, 2025, highlighting serious concerns over the company's transparency.
- False Statements Allegations: The lawsuit alleges that Ultragenyx made misleading statements regarding the efficacy of its drug setrusumab in the Phase III Orbit study, failing to disclose the risk that patients might not achieve a statistically significant reduction in annualized fracture rate, potentially leading to misjudgments about the company's prospects.
- Investor Action: Affected investors must apply for lead plaintiff status by April 6, 2026, to represent all impacted investors in the litigation, indicating a proactive stance and engagement from the investor community in legal proceedings.
- Law Firm's Role: Kessler Topaz Meltzer & Check, LLP is a leading law firm focused on securities fraud class actions, representing both individual and institutional investors, underscoring its significance in safeguarding investor rights.
See More
Ultragenyx Pharmaceutical Class Action Notice Issued
- Shareholder Lawsuit Notice: The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), encouraging those who purchased shares during the class period from August 3, 2023, to December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- False Statements Allegations: The complaint alleges that Ultragenyx provided overwhelmingly positive statements while concealing significant adverse facts about setrusumab's potential, misleading investors and impacting their decision-making regarding the company's future.
- Clinical Trial Failure: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints, resulting in a dramatic stock price drop of approximately 42.32% in one day, from $34.19 to $19.72, severely undermining investor confidence.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected during the legal proceedings.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock between August 3, 2023, and December 26, 2025, highlighting investor concerns over potential risks associated with the company.
- Study Results Fail: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing clinical fracture rates, leading to a dramatic stock price drop of approximately 42.32% in a single day, from $34.19 to $19.72 per share, reflecting market disappointment in the company's prospects.
- Misleading Statements: The lawsuit alleges that the company provided overly optimistic statements to investors regarding setrusumab's ability to significantly reduce fracture rates, while the study designs and outcomes were not as effective as claimed by management, causing investors to purchase shares at artificially inflated prices.
- Investor Action Advice: Affected shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs, emphasizing the importance of corporate governance and accountability of management in light of the allegations.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta patients, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff to share in any potential recovery, indicating the urgency and importance of investor participation in the legal process.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx and Mereo Face Class Action Lawsuits
- Lawsuit Background: Bragar Eagel & Squire, P.C. has alerted investors that Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc are facing class action lawsuits, with a deadline of April 6, 2026, for investors to apply as lead plaintiffs, indicating significant investor concern over potential risks associated with these companies.
- Ultragenyx Lawsuit Details: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing fracture rates, causing its stock price to plummet from $34.19 to $19.72, a decline of 42.32%, reflecting market disappointment in the study results.
- Mereo Lawsuit Details: Mereo BioPharma faces similar allegations as its Phase 3 ORBIT and COSMIC studies did not meet the primary endpoint of reducing annualized fracture rates, leading to a drastic drop in its stock price from $2.31 to $0.29, a decline of over 87.7%, showcasing extreme investor pessimism regarding its prospects.
- Investor Impact: Both companies are accused of failing to disclose research risks adequately, resulting in shareholders purchasing stocks at inflated prices; the initiation of class action lawsuits may severely impact their future financing and market confidence, exacerbating investor anxiety.
See More
